carmustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 245 Diseases   54 Trials   54 Trials   1419 News 


12345678910111213...2021»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial initiation date:  MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (clinicaltrials.gov) -  Sep 19, 2024   
    P2,  N=28, Not yet recruiting, 
    In conclusion, our work suggests that combining let-7a-3p replacement therapy with carmustine treatment could be considered a promising strategy in treatment and can increase efficiency of glioblastoma chemotherapy. Initiation date: Aug 2024 --> Dec 2024
  • ||||||||||  The Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma () -  Aug 30, 2024 - Abstract #SOHO2024SOHO_1030;    
    P1, P1/2,
    Additionally, studies assessing the efficacy and safety of iberdomide (NCT06179888) and mezigdomide (NCT06048250) as maintenance agents post idecabtagene vicleucel are underway...Furthermore, a distinct benefit to patients currently receiving CAR-T is the possibility of experiencing a prolonged treatment-free interval afterwards,25 and the routine prescription of maintenance will change this radically. Moreover, maintenance therapy after CAR-T may also lead to increased patient financial toxicity and increase financial burdens on health care systems,26 noting the already high cost of CAR-T therapies.
  • ||||||||||  temozolomide / Generic mfg., carmustine / Generic mfg.
    Review, Journal:  Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in gastrointestinal cancers. (Pubmed Central) -  Aug 21, 2024   
    This review explores the structural functions and repair processes of MGMT, focusing on the putative structural and functional significance of the N-terminal domain of MGMT. It also investigates the advancement of cancer treatment techniques that specifically target MGMT.
  • ||||||||||  LACTIC ALKALOSIS: A DECEPTIVE NAME FOR A DECEPTIVE LAB FINDING (Convention Center Exhibit Hall: Poster Area 4) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1728;    
    She was admitted to Oncology with subsequently negative cardiac and infectious workup for her dyspnea and was started on empiric steroids for possible carmustine pneumonitis...She was not taking nicotine replacement, beta agonists, or progesterone containing medications...She was given morphine as needed to suppress her respiratory drive with subsequent rapid improvement in her lactate level to 1.9... Patients with alkalosis may develop compensatory lactic acid generation, and in cases such as this one with central neurogenic hyperventilation an elevated lactic acid level may be misleading and invite inappropriate diagnostic anchoring.
  • ||||||||||  carmustine / Generic mfg.
    Review, Journal:  Local therapy in glioma: An evolving paradigm from history to horizons (Review). (Pubmed Central) -  Jul 31, 2024   
    In total, three primary reasons have thus led to the development of numerous LT solutions in recent decades: i) Intratumoral implants allow the blood-brain barrier to be bypassed, resulting in limited systemic toxicity; ii) LT facilitates bridging therapy between surgery and standard treatments; and iii) given the complexity of GBM, targeting multiple components of the tumor microenvironment through ligands specific to various elements could have a synergistic effect in treatments. Considering the spatial and temporal heterogeneity of GBM, the disease prognosis could be significantly improved by a combination of therapeutic strategies in the era of precision medicine.
  • ||||||||||  melphalan / Generic mfg.
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov) -  Jun 21, 2024   
    P1,  N=40, Recruiting, 
    Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Phase classification: P=N/A --> P1 | N=20 --> 40 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  lomustine / Generic mfg., temozolomide / Generic mfg., carmustine / Generic mfg.
    Biomarker, Journal:  System biology approach to identify the novel biomarkers in glioblastoma multiforme tumors by using computational analysis. (Pubmed Central) -  Jun 6, 2024   
    Clinicaltrials.gov (NCT01511562). Molecular docking investigations indicated that the chosen complexes (carmustine, lomustine, marimastat, and temozolomide) had high binding affinities of -6.3, -7.4, -7.7, and -8.7 kcal/mol, respectively, the mean root-mean-square deviation (RMSD) value for the carmustine complex and marimastat complex was 4.2
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial primary completion date, IO biomarker:  Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) -  May 16, 2024   
    P3,  N=302, Active, not recruiting, 
    US knowledge in NEC diagnosis allows to have comparable days of hospitalization of patients NECpos vs. patients NECneg. The cost analysis of NECpos vs. NECneg has been also performed. Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Relapse Hodgkin lymphoma autologous stem cell transplant long term follow up. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4999;    
    The preparative regimen was carmustine, etoposide, and melphalam (CEM, 1992-2005) and BCNU, etoposide, cytarabine and melphalan (BEAM, 2006 to present)...All patients underwent mobilized peripheral blood stem collections with high dose filgrastim, and starting in 2008 were mobilized with both filgrastim and plexiform... Patients with relapsed HL can achieve long term curative outcomes when treated with ABMT with most frequent long term complication being cardiomyopathy.
  • ||||||||||  VBI-1901 / VBI Vaccines
    Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas. (Hall A; Poster Bd #: 393b) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3205;    
    P1/2
    400/uL at screening are eligible, as people with a preserved immune system are more likely to respond to immunization with VBI-1901 based on the initial phase study...This hazard ratio corresponds to a difference in the mOS observed previously with VBI-1901 and a historical mOS of 8 months in the SOC group. As of January 31 st 2024 , 12 of 60 patients have been randomized and dosed across 8 US sites.
  • ||||||||||  Review, Journal, CAR T-Cell Therapy:  Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases. (Pubmed Central) -  Apr 5, 2024   
    In case of acute lymphoblastic leukemia (ALL), BU, fludarabine, and etoposide (BuFluVP) conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence...With respect to Hodgkin's lymphoma, mitoxantrone (MITO)/MEL overtook carmustine, VP16, cytarabine, and MEL in view of PFS and vice versa regarding OS...Lastly, amyloidosis was considered, and the regimen that proved to be competent was MEL 200 (200 mg/m2). This review article demonstrates a comparison between various conditioning regimens employed in different diseases.
  • ||||||||||  Mustargen (mechlorethamine) / Recordati, Onrigin (laromustine) / Vion
    Targeting the repair of DNA-protein crosslinks induced by bifunctional alkylating agents (Section 22) -  Mar 5, 2024 - Abstract #AACR2024AACR_9344;    
    Chemotherapeutic sensitization by targeting SPRTN could suggest a therapeutic strategy to improve effectiveness of several DNA-targeted anticancer agents, especially if extended to other therapeutics that trap DPCs such as inhibitors of topoisomerase and poly(ADP-ribose) polymerase. Further, identifying structure-function relationships with respect to bifunctional alkylating agents and DPC formation could inform the future development and clinical utilization of these chemotherapies.
  • ||||||||||  Reckless mitotic entry as a chemosensitization approach for alkylating agents (Section 23) -  Mar 5, 2024 - Abstract #AACR2024AACR_6721;    
    In this study, we conducted a forward genome scale CRISPR/Cas9 chemogenomic screening with repeated exposure to the alkylating agent temozolomide (TMZ) to investigate the mechanisms underlying tumor cell survival under genotoxic stress...Isobologram analysis demonstrated potent drug synergy between TMZ and other clinically used alkylating agents, such as carmustine, busulfan, and dacarbazine, when combined with a novel Myt1 kinase inhibitor, RP-6306...Importantly, preclinical animal studies demonstrated that the combination regimen involving TMZ and RP-6306 prolonged the overall survival of glioma-bearing mice. Collectively, our findings highlight the potential of targeting cell cycle timing through Myt1 inhibition as an effective strategy to enhance the efficacy of current standard cancer therapies, potentially leading to improved disease outcomes.
  • ||||||||||  carmustine / Generic mfg.
    Preclinical, Journal:  The investigation of cytotoxic and apoptotic activity of Cl-amidine on the human U-87 MG glioma cell line. (Pubmed Central) -  Feb 27, 2024   
    We propose that the antineoplastic properties of Cl-amidine should be further investigated through a broader spectrum of cancer cell types. Moreover, we believe that investigating the synergistic interactions of Cl-amidine with single or combination therapies holds promise for the discovery of novel anticancer agents.
  • ||||||||||  cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
    Trial completion date, Trial primary completion date:  Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) -  Feb 22, 2024   
    P1,  N=25, Active, not recruiting, 
    Moreover, we believe that investigating the synergistic interactions of Cl-amidine with single or combination therapies holds promise for the discovery of novel anticancer agents. Trial primary completion date: Dec 2023 --> Dec 2024 | Trial completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Enrollment change:  Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=53, Active, not recruiting, 
    Trial completion date: Apr 2027 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Mar 2028 N=80 --> 53
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    PHARMACEUTICAL INTERVENTIONS WITHIN A BMT/ CART PREHABILITATION SERVICE  (GALA) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2243;    
    Pharmaceutical considerations were often multifactorial, particularly in the CART cohort and required a holistic review of overall management. Translation of interventions into clinical practice is supported by pharmacist prescribing of the admission drug chart.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    MODIFIED GIAC CONDITIONING REGIMEN IN HAPLOIDENTICAL TRANSPLANT: SINGLE CENTRE STUDY (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2014;    
    HLA-mismatched/haploidentical HSCT was feasible with unmanipulated blood harvest in a modified GIAC conditioning regimen. Modified GIAC protocol for mismatched hematopoietic stem cell transplantation is relatively safe and efficient for patients with haematological malignancies